Premium
Effect of estrogen/gestagen and 24 R ,25‐dihydroxyvitamin D 3 therapy on bone formation in postmenopausal women
Author(s) -
Thomsen Karsten,
Riis Bente,
Christiansen Claus
Publication year - 1986
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650010604
Subject(s) - endocrinology , medicine , bone remodeling , estrogen , placebo , alkaline phosphatase , excretion , cholecalciferol , vitamin d and neurology , chemistry , enzyme , biochemistry , alternative medicine , pathology
The effect of two different estrogen/gestagen regimens and 24 R ,25‐(OH) 2 ‐cholecalciferol on bone formation was studied in a randomized trial with 144 healthy postmenopausal women. Urinary excretion (UE) of 99 m ‐technetium‐diphosphonate and serum alkaline phosphatase (AP) was determined before and then once a year for 2 years of treatment. Both estimates of bone formation showed highly significant decreases ( p < .001) to normal premenopausal levels in women receiving unopposed 17β‐estradiol or in a sequential combination with progestagen, whereas unchanged high values were found in the groups receiving 24 R ,25‐(OH) 2 D 3 and placebo. The data show that bone turnover increases in early postmenopausal women concomitantly with the loss of bone mass, and that hormonal substitutional therapy normalizes the total skeletal turnover as well as preventing bone loss.